[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634334":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":37,"locations":46,"responsibleParty":67,"collaborators":25,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":25,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":90,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part I (finding the right dose)","ACTIVE_COMPARATOR","Small groups of participants will receive different doses of emapalumab through an IV (into a vein). The goal is to find the dose that best blocks harmful inflammation in the lungs.",[13],"Drug: Emapalumab",{"label":15,"type":6,"description":16,"interventionNames":17},"Part 2 (testing how well it works)","Participants will receive the selected dose of emapalumab or placebo. Doctors will:\n\nMonitor blood and lung markers Check for viruses Follow your progress weekly for about 4 weeks",[13,18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Emapalumab","This is a one-time infusion",[15,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","This is a one-time infusion of inactive drug",[15],[31,34],{"name":32,"affiliation":5,"role":33},"John Greenland, Dr.","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"John Belperio, Dr.","University of California, Los Angeles",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Legna Betancourt","CONTACT","(415) 476-8073","legna.betancourt@ucsf.edu",{"name":44,"role":40,"phone":25,"phoneExt":25,"email":45},"Principal Investigator","john.greenland@ucsf.edu",[47,59],{"facility":36,"status":25,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":25},"Los Angeles","California","90095","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-118.24368,34.05223,{"lat":57,"lon":56},{"facility":5,"status":25,"city":60,"state":49,"zip":61,"country":51,"countryCode":52,"cosmosGeoPoint":62,"geoPoint":66,"contacts":25},"San Francisco","94143",{"type":54,"coordinates":63},[64,65],-122.41942,37.77493,{"lat":65,"lon":64},{"type":68,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100634334","phase-2-targeting-interferon-gamma-with-emapalumab-to-lung-transplant-recipients-with-interferon-gamma-high-acute-lung-allograft-dysfunction-100634334",false,"NCT07538336","Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction","TIGER-Lung","Inclusion Criteria:\n\n* Recipients ≥10 months post-lung transplant who are enrolled in existing biorepository study (IRB #13-10738) will be approached if they have ALAD and elevated AI2 and CXCL9 levels\n* Age: ≥18 years old\n* Informed Consent: Ability to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Active Bacterial Infection: Positive bacterial cultures from bronchoalveolar lavage (BAL) samples at the time of ALAD diagnosis. Viral infections, which are typically treated in lung transplant recipients with a steroid taper and cleared by type I interferons, are not exclusion criteria per se.\n* Active CMV or EBV Infection: Active reactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV) based on plasma PCR testing.\n* Severe Comorbidities: Presence of severe conditions likely to compromise study participation or outcomes (e.g., terminal illness).\n* Pregnancy or Breastfeeding: Women who are pregnant or breastfeeding at the time of screening.\n* Concurrent Immunosuppressive Therapy Trials: Use of investigational agents or therapies other than standard of care post-transplant immunosuppression.\n* Allergy to Study Drug: Known hypersensitivity to emapalumab or any of its components.\n* Insufficient Baseline Data: Lack of prior baseline FEV1 data for comparison.","ALL","18 Years",{"count":79,"type":80},40,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This study is testing a medication called emapalumab to see if it can help people who have had a lung transplant and are experiencing a sudden drop in lung function, called acute lung allograft dysfunction (ALAD).\n\nALAD is a serious condition that can happen after a lung transplant and can lead to worsening breathing and other complications. Right now, there is no approved treatment for ALAD.\n\nThe main goal is to see if lung function improves, meaning it returns close to your usual (baseline) level within 90 days.",[86],"Lung Transplant",[88,89,86],"ALAD","Acute Lung Allograft Dysfunction","NOT_YET_RECRUITING","2026-04-15",{"date":93,"type":94},"2026-04-20","ACTUAL",{"date":96,"type":80},"2026-11-02",{"date":98,"type":80},"2028-11-01",{"name":5,"class":6},2]